Search Results 2071-2080 of 19670 for hemoglobin

1. A Study of Catequentinib, Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma - Mayo Clinic

   Platelet count ≥ 100,000 cells/mm^3, hemoglobin ≥ 9 g/dL, absolute neutrophil count ≥ 1,500 cells/mm^3. Alkaline phosphatase limit ≤ 2.5 x ULN (< 5 x ...

2. Orthopedic Surgery - Clinical trials

   ... hemoglobin levels, 90-day complications, readmission and reoperation. Pagination Clinical studies. PrevPrevious Page · Go to page 11 · Go to page 22 · Go to ...

3. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

   - Hemoglobin >= 9.0 g/dl - Platelets >= 100,000/mcL - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (Patients with known Gilbert ...

4. Clinical trials - Oncology (Medical)

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

5. Clinical trials - Oncology (Medical)

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

6. Testing Teclistamab (TECVAYLI) In Combination With Iberdomide For Hard-to-Treat Multiple Myeloma - Mayo Clinic

   * Hemoglobin ≥ 7.0 g/dL ( ≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past ...

7. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

   Hemoglobin >7.0 g/dL; Absolute neutrophil count (ANC) ≥1000/mcL; growth factor support allowed at physician discretion. Platelet count ≥75,000/mcL; Total ...

8. A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with GRPR+, ER+, HER2- metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibito - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL;; International Normalized Ratio (INR) ≤ 1.5;; Creatinine Clearance ≥ 60 mL/min using the Chronic Kidney Disease Epidemiology ...

9. Ulixertinib in People With Histiocytic Neoplasms - Mayo Clinic

   Adequate bone marrow function (hemoglobin ≥9.0 g/dL, platelets ≥100 x 10^9 cells/L, absolute neutrophil count ≥1.5 x 10^9 cells/L). Patients with ...

10. Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment);; Absolute neutrophil count ≥1500/mm3 ...